Sunshine Biopharma Series B warrant price $1.2046
Recent at-the-market common stock sales reduced Sunshine Biopharma’s Series B warrant exercise price to $1.2046, with possible future adjustments.
Rhea-AI Filing Summary
Sunshine Biopharma Inc. (SBFM) reports a change to the terms of its outstanding Series B Warrants. Due to recent sales of its common stock under a previously disclosed at-the-market offering, the exercise price of these Series B Warrants has been reduced to $1.2046 per share, subject to further adjustment as provided in the warrant terms.
The company’s common stock (par value $0.001) trades under the symbol SBFM and its common stock purchase warrants trade under SBFMW on The Nasdaq Stock Market LLC.
Positive
- None.
Negative
- None.
Filing Explained
The September 11, 2026 Form 8-K reports that the exercise price for the outstanding Series B Warrants has been reduced to
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Series B Warrant exercise price: $1.2046 per share
Common Stock par value: $0.001 per share
Trading symbols: SBFM (Common Stock), SBFMW (Common Stock Purchase Warrants)
+1 more
4 metrics
Series B Warrant exercise price
$1.2046 per share
Adjusted exercise price for outstanding Series B Warrants as of the report date
Common Stock par value
$0.001 per share
Par value of Sunshine Biopharma’s common stock listed on Nasdaq
Trading symbols
SBFM (Common Stock), SBFMW (Common Stock Purchase Warrants)
Securities registered on The Nasdaq Stock Market LLC
Principal phone number
(954) 330-0684
Registrant’s telephone number for principal executive offices
Key Terms
at-the-market offering, Series B Warrants, exercise price, emerging growth company
4 terms
at-the-market offering financial
"due to recent sales of ... common stock under the Company’s previously disclosed at-the-market offering"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
Series B Warrants financial
"the exercise price of the Company’s outstanding Series B Warrants has been reduced"
Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.
exercise price financial
"the exercise price of the Company’s outstanding Series B Warrants has been reduced to $1.2046"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What change did Sunshine Biopharma (SBFM) announce regarding its Series B Warrants?
Sunshine Biopharma announced that the exercise price of its outstanding Series B Warrants has been reduced to $1.2046 per share, with the price remaining subject to further adjustment under the terms of the Series B Warrants.
Why was the Series B Warrant exercise price for SBFM reduced to $1.2046?
The exercise price was reduced to $1.2046 because of recent sales of Sunshine Biopharma’s common stock conducted under its previously disclosed at-the-market offering, which triggered an adjustment mechanism in the Series B Warrants.
Can the $1.2046 Series B Warrant exercise price at Sunshine Biopharma change again?
Yes. The company states that the $1.2046 exercise price for its outstanding Series B Warrants is subject to further adjustment as set forth under the applicable Series B Warrant terms.
What securities of Sunshine Biopharma (SBFM) are listed on Nasdaq?
Sunshine Biopharma lists its Common Stock, par value $0.001, under symbol SBFM and its Common Stock Purchase Warrants under symbol SBFMW on The Nasdaq Stock Market LLC.
What type of equity financing is referenced in Sunshine Biopharma’s 8-K?
The filing references an existing at-the-market offering of Sunshine Biopharma’s common stock. Recent sales under this at-the-market program caused the adjustment of the Series B Warrant exercise price to $1.2046.
AI-generated analysis. How Rhea-AI works. Not financial advice.
